Clostridium Difficile (C Diff.) Study

Effective treatment of C. diff infections is critical, but how do we prevent the problem of recurrences?

Recurrence of Clostridium difficile infection (CDI) is a key unmet medical need in the management of CDI:

  • Occurs in up to 30% of patients following initial therapy
  • Significant burden on patients due to increased morbidity and diminished quality of life
  • Associated with an increased risk of further recurrent episodes and an increase in severity

Learn how to participate in the Ri-CoDIFy study investigating an antibiotic that has the potential to not only effectively treat CDI but also to reduce disease recurrence typically seen with standard of care antibiotic treatments.

To qualify for this study, a patient must:

  • Be at least 18 years of age, at the time of signing the informed consent
  • Have signs and symptoms of CDI including diarrhea such that in the Investigator’s opinion CDI antimicrobial therapy is required.

*Other qualifications may apply.

Qualified participants will receive:

  • Study-related medication at no cost
  • Study-related medical exams at no cost
  • Compensation for time and travel

If you are interested in participating in our clostridium difficile study, please fill out the form below or call us at (423) 698-4584.

Please provide the following information so that we can contact you regarding enrolling in our current and upcoming studies. Provide only information you feel comfortable transmitting to our secure website via the internet. Your information will NOT be shared with anyone else and will only be used to contact you regarding potential involvement in our studies and for sending you study related newsletters and mailings.